

# Ethical issues in the use of financial incentives to improve hepatitis C clinic attendance.

Dr Ray Poll

Nurse Consultant for Viral Hepatitis

Sheffield Teaching Hospitals

# Aim of presentation

To provide some key guidance for those considering the use of incentives in their practice or research.

# Outline

- Hepatitis C
- Behaviour change model
- Literature review of incentives
- Incentive feasibility study
- Practical and ethical issues of financial incentives for improving clinic attendance
  - 5 themes
- Conclusion

# Hepatitis C




Spare a thought for that empty chair:  
it could be costing more than you think...



**Cannot keep your appointment?**  
Let us know and we can give it to someone else.

# Behaviour change (COM-B)



Lit Review Extraction tool - Microsoft Excel							
	A	B	C	D	E	F	
1	Author(s)	Title	Publication Date & Journal	Population	Type of incentive	Sample size	Results
	Anke Groß et al.	A comparison Between Low-Magnitude Voucher and Buprenorphine Medication Contingencies in Promoting Abstinence From Opioids and Cocaine.	2006. Experimental and Clinical Psychopharmacology.	Participants recruited with history of past or current opioid use via variety of adverts. Study undertaken in outpatients at Substance Abuse Treatment Clinic of the University of Vermont (USA).	Points earned recorded on vouchers. First negative urine specimen worth 29 points at \$0.125 per point, or \$3.63. Each subsequent consecutive negative specimen increased the value of the voucher by 1 point (e.g. 30 points for the second, 31 points for the third etc). A \$5 bonus was provided to patients for each set of three consecutive negative samples. Continuous abstinence throughout the 12 week-period (weeks 9-20) during which these contingencies were imposed resulted in a patient receiving vouchers equivalent to a total of \$269. The cash equivalent of the points earned by patients were used by staff to buy material reinforcers requested by patients (e.g. fishing licences, restaurant gift certificates, automobile parts etc). Submission of an opioid- and/or cocaine-positive urine sample or failing to submit a scheduled specimen was counted as positive, and the next negative sample for both drugs reset the value of vouchers to the initial \$3.63 level. Submission of five consecutive opioid- and/or cocaine-negative specimens returned the value of the vouchers to the level obtained before the reset.	Total of 60 participants randomly assigned to either (a) Voucher (b) Medical contingency (c) Control. Twenty participants in each group.	There was no significant difference between groups. There were also no significant differences in who completed participants and durations of contingency group. Participants in either of the groups did not differ significantly. Post-contingency possible \$269. F
12	Edward P Post, Mario Cruz and Jeffrey Harman.	Incentive Payments for Attendance at Appointments for Depression Among Low-Income African Americans.	2006. Psychiatric Services.	Low income African-American with depression at a clinic affiliated with a university mental health centre (USA).	A second 12 weeks of \$10 payments at the conclusion of each regularly scheduled appointment (usually weekly, but solely at the therapist's discretion).	60 patients referred to the study. Of these 58 were eligible, and 54 enrolled after providing informed consent. Four participants discontinued care at the clinic before incentives began. Thus, leaving 50 participants.	Twenty seven of participants (24% and 11 (22%) had adherence from post-incentive periods 2 and 3. After adjustment Payments during adherence to 86% all period 1 appointment adherence decrease payments. Compared to 11% (n=27 of 2 scores between
13	Jennifer Plebani Lussier et al.	A meta-analysis of voucher-based reinforcement therapy for substance use disorders.	2005 Addiction	Drug use	Mean voucher earnings per day. < \$5 daily; \$5.00 to \$10.99; and \$11.00 to \$16.00.	30 studies targeting abstinence were examined to determine whether, and by how much, VBRT improved outcomes (i.e. greater amount of biochemically verified abstinence). 10 studies targeted outcomes other than abstinence - n=6 attendance and n=4 medication compliance.	The only variable immediacy of abstinence (n=20 using more delay involving maximum while those effects was no significant analyses. The duration studies (N=3) were but was not a significant average daily voucher effect sizes in immediate delivery earnings were. Attendance studies medication compliance 0.47), although
14	Alicia R Pollastri et al.	Incentive Program Decreases Non-Shows in Nontreatment Substance	2005 Experimental and Clinical	Outpatient research centre in New Haven, Connecticut, USA. Participants in a study	\$75 and a prize or combination of prizes to the value of 10 points (approx. \$15). For example 1 point prize - bar of soap, toothbrush, packet of cookies; 5 point	Control group (before the intervention) - 226 participants; 183 participants offered the	No difference in non-shows at the first appointment was 58.7%. There were no significant differences in the rate of non-shows in the individuals who intervention. Control in the rate of advance

# Literature review for incentives

- 22 papers – mainly USA
- Populations – Tuberculosis, Illicit Drug Use, Mental Health, Sexual Health
- Behaviour – Abstinence, Treatment (immunisation) adherence, Attendance
- Incentive – Cash, voucher, prize draw, goods, [fixed/variable/escalating/immediate/delayed]
- Hepatitis C – treatment completion and achieved sustained viral response; cash (fixed vs lottery)

# Incentive feasibility study

- Grant application Health Services & Delivery Research
- Improve first appointment attendance at hospital hepatitis C clinics
- Methods right for larger trial
- £20 voucher and taxi (enabler)
- 8 sites across Yorkshire and Humber
  - 2 intervention sites
  - 6 control sites
- Outcomes
  - Routinely collected anonymised attendance data
  - Qualitative – participants interviews and staff focus group



# Practical and ethical issues for use of incentives

- Systematic review of acceptability of financial incentives (Relton et al, 2013)
- 6 studies – US, UK, Australia
- Design – focus groups, interviews, thematic content analysis, mixed methods survey
- Intervention - stopping smoking (pregnancy), antipsychotic maintenance medication, obtaining medication for hypertension
- Evaluation – thematic analysis, grounded theory

# Effectiveness and cost-effectiveness

- Prerequisite for acceptability
- £ as a “motivational” tool
- Effective for difficult to engage groups & where other intervention failed
- Spend now, save later
- Oppositional feelings (mass media attitudes)
- Misuse of money
- Money better spent on other services

# Monitoring, validation & practicalities

- Payment levels
- Practical administration of the financial incentive scheme
- Misuse of incentive money/deception

# Personal responsibility for health

- Extrinsic vs intrinsic motivators (State vs personal responsibility for health)
- Incentives as short-term fix
- Inappropriate rewards for problematic/unhealthy behaviour
- Practical administration of the financial incentive scheme
- Misuse of incentive money/deception

# Us vs Them


- Pattern of oppositional discourse
- ‘Good patients’ vs ‘Those people’
- ‘Good patients’
  - Commitment to improving their health
  - Act with responsibility
- ‘Those people’
  - ‘undeserving groups’
  - Less self control

# Relationships with healthcare providers

- Important the financial incentives are acceptable to both patients and healthcare providers.
- Difficulty reconciling a financial incentive with the collaborative relationship between patients and healthcare professional.
- Financial incentives are inherently coercive, unbalancing the delicate balance of trust (or lack of trust) and care.

# Conclusion

- Incentives just one intervention for behaviour change
- Incentives in different forms and used in different ways
- Several practical and ethical issues in their use
- Effectiveness & cost-effectiveness prerequisite for acceptability
- More research needed





# References

- Herrmann et al. (2017) Contingency Management Interventions for HIV, Tuberculosis, and Hepatitis Control Among Individuals With Substance Use Disorders: A Systematized Review. *J Subst Abuse Treat.*
- Wohl et al. (2017) Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies. *OFID.*
- Biggs et al. (2016) Deadly Liver Mob: opening the door – improving sexual health pathways for Aboriginal people in Western Sydney. *Sexual Health.*
- Lutge et al. (2015) Incentives *and* enablers to improve adherence in tuberculosis. *Cochrane Database of Systematic Reviews.*
- Fitzsimons et al. (2015) Clinician-delivered contingency management increases engagement and attendance in drug and alcohol treatment. *Drug & Alcohol Dependence.*
- Drummond et al. (2014) A randomized study of contingency management and spirometric lung age for motivating smoking cessation among injection drug users. *BMC Public Health.*
- Weaver et al. (2014) Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. *Lancet.*
- Acquavita et al. (2013) Client incentives versus contracting and staff incentives: how care continuity interventions in substance abuse treatment can improve residential to outpatient transition. *J Subst Abuse Treat.*
- Relton et al. (2013) Behaviour change in breastfeeding: are financial incentives acceptable? *Invited presentation at the British Association for Behaviour Change and Cognitive Psychotherapies (BABCP) conference, July 2013, Imperial College, London.*

# References (2)

- Schmitz et al. (2010) Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. *Experimental & Clinical Psychopharmacology*.
- Brigham et al. (2010) Incentives for retention of pregnant substance users: a secondary analysis. *J Subst Abuse Treat*.
- Leontieva et al. (2008) Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders. *Psychiatric Services*.
- Gross et al. (2006) A comparison between low-magnitude voucher and buprenorphine medication contingencies in promoting abstinence from opioids and cocaine. *Experimental & Clinical Psychopharmacology*.
- Post et al. (2006) Incentive payments for attendance at appointments for depression among low-income African Americans. *Psychiatric Services*.
- Lussier et al. (2006) A meta-analysis of voucher-based reinforcement therapy for substance use disorders. *Addiction*.
- Pollastri et al. (2005) Incentive program decreases no shows in non-treatment substance abuse research. *Experimental & Clinical Psychopharmacology*.
- Sigmon & Stitzer. (2005) Use of a low-cost incentive intervention to improve counselling attendance among methadone-maintained patients. *J Subst Abuse Treat*.
- Corrigan et al. (2005) Increasing substance abuse treatment compliance for persons with traumatic brain injury. *Psychology of Addictive Behaviors*.
- Petry et al. (2001) Reinforcing compliance with non-drug related activities. *J Subst Abuse Treat*.

# References (3)

- White et al. (1998) A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail. *International Journal of Tuberculosis & Lung Disease*.
- Elk et al. (1998) Cessation of cocaine use during pregnancy: effects of contingency management interventions on maintaining abstinence and complying with prenatal care. *Addictive Behaviors*.
- Zuckerman et al. (1996) Tuberculosis screening in a sexually transmitted diseases clinic. *Sexually Transmitted Diseases*.
- Rowan-Szal et al. (1994) A simple reinforcement system for methadone clients in a community-based treatment program. *J Subst Abuse Treat*.

# Disclaimer

The views and opinions expressed are those of the author(s), and not necessarily those of the NHS, the NIHR or the Department of Health.